Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical Group Company Limited has announced that its B7-H3-targeted antibody-drug conjugate, HS-20093, has been granted Breakthrough Therapy Designation by China’s National Medical Products Administration for treating small cell lung cancer. This promising development follows a licensing agreement with GlaxoSmithKline, which is conducting global trials of the drug. Such advancements could significantly impact Hansoh’s market position and attract investor interest.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.